PerkinElmer launches New AlphaLISA SureFire Ultra Assays

The company’s new solution reduces assay time and enhances detection process for lifescience researchers


An AlphaLISA SureFire Ultra assay generates results in less than 2.5 hours

PerkinElmer has added to its product line with the launch of its AlphaLISA SureFire Ultra assays. These solutions are designed to reduce assay time by up to 50 percent and to improve the protein phosphorylation detection process.  With high sensitivity and a wide dynamic range to detect protein phosphorylation, even at low levels, the assays are quick and easy to run even with a minimal amount of sample.

"PerkinElmer is committed to developing advanced solutions for screening virtually all types of samples while controlling the quality of therapeutic antibodies. Providing new assays that help improve the research and quality control process can lead to breakthroughs in the lab and development of new biotherapeutic treatments," said Mr Brian Kim, president, Lifesciences and Technology, PerkinElmer.

The AlphaLISA SureFire Ultra assays use TGR BioSciences' CaptSure technology to eliminate antibody interference in the therapeutic antibody screening process. It is also ideal for other types of screening such as small molecule modulation, detection of low and basal levels of phosphorylation, and detection of phosphorylation in tissue lysates.

It generates results in less than 2.5 hours with only one or two incubation steps and no washing. Researchers can analyse different endogenous or transfected targets in parallel, all on the same plate.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email